Compare Merck & Co., Inc. (MRK) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SkyWest Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while SkyWest Inc trades at $95.26 (market cap $3.94B). The key difference: Merck & Co., Inc. is far larger — about 78× SkyWest Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| MRK | SKYW | |
|---|---|---|
Market Cap | $307.25B | $3.94B |
Sector | Health | Technology |
52-Week High | $129.52 | $123.72 |
52-Week Low | $77.60 | $78.40 |
Enterprise Value | $350.66B | $5.79B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SkyWest (SKYW) trades at $99.34, up 2.17% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.52 and net income margin of 10.42%. Recent earnings beat expectations in Q1 2026, and analyst consensus is a buy with a $109.33 price target. The company announced a new president and COO in July 2026, signaling operational focus amid industry fuel cost pressures.
The outlook is positive given undervaluation and earnings momentum, but risks include elevated jet fuel expenses impacting airline profitability. Investor sentiment is supported by institutional buying and lack of sell ratings, though macroeconomic headwinds remain a key watchpoint for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
